This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Cancer Research Campaign Technology Limited, Duke University. Active years: 2000.
Company Filing History:
1 out of 62 
1 out of 2,075 
Years Active: 2000
Title: Michael Rudolf Stratton: Innovator in Cancer Genetics
Introduction
Michael Rudolf Stratton is a prominent inventor based in London, GB. He is known for his significant contributions to the field of cancer genetics, particularly in the identification and sequencing of the BRCA2 gene. His work has implications for understanding genetic predispositions to cancer, especially breast and ovarian cancer.
Latest Patents
Stratton holds a patent related to "Materials and methods relating to the identification and sequencing of the BRCA2 gene." This patent discloses the identification and sequencing of the BRCA2 gene, along with the amino acid sequence of the corresponding BRCA2 polypeptides. It also covers BRCA2 alleles, including those with mutations associated with a predisposition to develop cancer. The invention further relates to the uses of BRCA2 nucleic acid and polypeptides in diagnostic, prognostic, or therapeutic treatments for cancer. He has 1 patent in this area.
Career Highlights
Throughout his career, Stratton has worked with esteemed institutions, including Duke University and Cancer Research Campaign Technology Limited. His research has significantly advanced the understanding of genetic factors in cancer development.
Collaborations
Stratton has collaborated with notable scientists, including Phillip Andrew Futreal and Richard Francis Wooster. These collaborations have contributed to the advancement of cancer research and the development of innovative diagnostic methods.
Conclusion
Michael Rudolf Stratton's work in cancer genetics has made a lasting impact on the field. His innovative approaches to understanding the BRCA2 gene continue to influence cancer research and treatment strategies.